Evolus (EOLS) Other Non-Current Liabilities (2018 - 2021)
Evolus (EOLS) posted Other Non-Current Liabilities of $44.7 million for Q4 2021, up 794.8% on a QoQ basis from $5.0 million in Q3 2021, and up 7.69% year-over-year from $41.5 million in Q4 2020.
Evolus (EOLS) Other Non-Current Liabilities (2018 - 2021) Analysis & Trends
Evolus' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $44.7 million for Q4 2021.
- Quarterly Other Non-Current Liabilities rose 7.69% year-over-year to $44.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $44.7 million (up 7.69% YoY) and the FY2021 annual result came in at $44.7 million, up 7.69% from the prior year.
- Other Non-Current Liabilities was $44.7 million for Q4 2021 at Evolus, up from $5.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $51.1 million in Q3 2018 and bottomed at $5.0 million in Q1 2021.
- A 4-year average of $35.7 million and a median of $44.7 million in 2019 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2019 — Other Non-Current Liabilities advanced 13.05% — and 2021, when it tumbled 85.39%.
- Evolus' Other Non-Current Liabilities stood at $50.2 million in 2018, then retreated by 10.99% to $44.7 million in 2019, then decreased by 7.02% to $41.5 million in 2020, then grew by 7.69% to $44.7 million in 2021.
- Business Quant data shows EOLS's Other Non-Current Liabilities at $44.7 million in Q4 2021, $5.0 million in Q3 2021, and $5.0 million in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 44.74 Mn |
| Sep 30, 2021 | 5.00 Mn |
| Jun 30, 2021 | 5.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Dec 31, 2020 | 41.55 Mn |
| Mar 31, 2020 | 34.22 Mn |
| Dec 31, 2019 | 44.68 Mn |
| Jun 30, 2019 | 47.17 Mn |
| Mar 31, 2019 | 45.90 Mn |
| Dec 31, 2018 | 50.20 Mn |
| Sep 30, 2018 | 51.10 Mn |
| Jun 30, 2018 | 48.80 Mn |
| Mar 31, 2018 | 40.60 Mn |